A Digital, Interactive, Decision-Support Algorithm to Facilitate and Improve the Hepatocellular Carcinoma Care Cascade in Adults: Integrating the Barcelona Clinic Liver Cancer (BCLC) Staging System and United Network for Organ Sharing (UNOS) Down-Staging Criteria into One Tool

¹Veterans Affairs Palo Alto Healthcare System, Stanford University School of Medicine, Palo Alto, California, USA; ²Mayo Clinic, Phoenix, Arizona, USA; ³University of Miami, Miami, Florida, USA; ⁴Baylor College of Medicine, Houston, Texas, USA; ⁵Northwestern University, Chicago, Illinois, USA; ⁶University of California, San Francisco, San Francisco, California, USA; ¹ ⁷University of Texas Southwestern Medical Center, Dallas, Texas, USA; ⁸Stanford University, Palo Alto, California, USA CLDF



Background

- Hepatocellular carcinoma (HCC) is the most common type of hepatic cancer; approximately 70%–90% of patients with HCC have an established background of chronic liver disease.^{1,2}
- Effective implementation of HCC screening and surveillance in patients with cirrhosis is associated with improved diagnosis of HCC at an early stage, increased likelihood of curative treatment, and improved overall survival. However, sup-optimal HCC screening and surveillance has led to a high proportion of HCCs being detected at advanced stages.
- Several HCC staging systems exist, but none are universally adopted; the Barcelona Clinic Liver Cancer (BCLC) staging system and the United Network for Organ Sharing-Down Staging (UNOS-DS) criteria are both widely used staging systems that offer distinct advantages.
- Data suggest that a decision-support tool can impact healthcare professional treatment decisions in a rapidly evolving therapeutic landscape, potentially improving patient care.⁴
- Worldwide, digital devices are improving every stage of the HCC patient care pathway.⁵
- Clinicians would benefit from a digital, decision-support tool for HCC that combines widely used and clinically proven screening and staging systems.

Methods

- The Chronic Liver Disease Foundation (CLDF) is a nonprofit educational organization dedicated to increasing awareness of the impact of chronic liver disease in the US.
- The CLDF has assembled a group of HCC experts, who are also members of the CLDF, to form the HCC Steering Committee.
- This committee identified a need for practical, point-of-care tools to assist healthcare professionals in the screening, staging, and management of patients with HCC.
- A small working group, that contained steering committee members, was formed and tasked with creating clinical care recommendations on the screening and staging of HCC that can be made readily available as an interactive and "living" web-based resource for providers.


Conclusions

- The algorithms proposed are based on extensive discussion among expert clinical hepatologists.
- These proposed interactive algorithms will be posted on the CLDF website for review by health-care providers.
- The algorithms will be updated, as appropriate, and will be used as educational tools for health care providers.



Scan the QR code to learn more about the interactive digital algorithm!

Robert J. Wong, MD¹; Channa Jayasekera, MD²; Patricia Jones, MD³; Fasiha Kanwal, MD⁵; Neil Mehta, MD⁶; Amit Singal, MD⁷; Aijaz Ahmed, MD⁸



*For more information on "The Liver Imaging Reporting And Data System (LI-RADS)", visit AFP, alpha-fetoprotein; HBV, hepatitis B virus; HDV, hepatitis D virus.

Very Early Stage (0)	Early Stage (A)	Interme
Single ≤2 cm	Single, or ≤3 nodules, each ≤3 cm	Mu
Preserved liver function*, PS 0	Preserved liver function*, PS 0	Preserved li
Refer to Hepatology or Liver Transplant Program for consideration for: Liver transplantation Surgical hepatic resection	Refer to Hepatology or Liver Transplant Program for consideration for: Liver transplantation Surgical hepatic resection Locoregional therapy	

ALBI, albumin-bilirubin.

Stage	Additional Criteria to Consider		
	MILAN Criteria or UNOS Exception Criteria for Waitlisting for Liver Transplant Surgery	UNOS Downstaging Criteria	Alpha-Fetoprotein (AFP) Criteria
Very Early Stage (0)	Single HCC lesion <5 cm or up to 3 HCC lesions all <3 cm with no extrahepatic spread of HCC.		
Early Stage (A)		A single HCC lesion 5.1–8cm. Two to three HCC lesions \leq 5 cm. Four to five HCC lesions \leq 3 cm. Total Tumor Diameter (TTD) must be \leq 8 cm with no extrahepatic	If initial AFP level was >1,000 ng/mL, it must drop to less than 500 ng/mL following DS by LRT to qualify for waitlisting for LT with UNOS Exception Criteria.
Intermediate Stage (B)			
Advanced Stage (C)			
Terminal Stage (D)		spread of HCC. HCC must be downstaged to Milan Criteria by locoregional therapy (LRT) for automatic waitlisting for liver transplantation (LT) with an HCC exception by UNOS (United Network of Organ Sharing).	



Supported by educational grants from AstraZeneca and Exelixis, Inc.

www.chronicliverdisease.org

